Cyclin D1‐CDK4/6 signaling has been associated with immune infiltration and responses.[3, 4] Targeting cyclin D1‐CDK4/6 signaling with CDK4/6i can affect antitumor responses by influencing both tumor cells and the TME.[31] However, mechanisms underlying the synergistic effects of CDK4/6 inhibitors and ICB and optimal combination strategies remain unclear. The gene discussed is CDK4; the disease is neoplasm.